ROBERT SWEETEN: Open Payments
NPI 1164509766 · NEOSHO, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$686 in 38 payments from 13 companies in 2025. Trend: 2023 $815 · 2024 $993 · 2025 $686
Food & beverage: $686
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $146 |
| Novo Nordisk Inc | 9 | $139 |
| AstraZeneca Pharmaceuticals LP | 6 | $136 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $82 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $31 |
| Abbott Laboratories | 1 | $24 |
| Janssen Pharmaceuticals, Inc | 1 | $24 |
| Lilly USA, LLC | 1 | $21 |
| PFIZER INC. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
Products named: REXULTI, FARXIGA, Ozempic, CAPLYTA, XIFAXAN, FREESTYLE LIBRE, SPRAVATO, ABILIFY MAINTENA.
Industry payments across MO — which companies pay providers there.
